Physician profile
Tammy Mitchell
NPI 1194838078
$1,615.94
in general payments reported to CMS, 2019-2025
22 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $192 · 2022: $170 · 2023: $201 · 2024: $273 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $681.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $362.28 | 2022-2025 | Epclusa |
| Novo Nordisk INC | $226.16 | 2019-2024 | Wegovy |
| Allergan, INC. | $136.30 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $122.58 | 2024-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.52 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.88 | 2022-2025 | Caplyta |
| Amgen INC. | $77.98 | 2019-2025 | Repatha, Repatha, Otezla |
| Astellas Pharma US INC | $66.79 | 2019-2023 | Veozah |
| Astrazeneca Pharmaceuticals Lp | $60.17 | 2019-2020 | |
| Glaxosmithkline, LLC. | $55.56 | 2019-2020 | |
| Pfizer INC. | $45.03 | 2024 | |
| Indivior INC. | $41.93 | 2024 | Perseris |
| Amarin Pharma, INC. | $38.78 | 2019-2020 | |
| Insulet Corporation | $37.10 | 2024-2025 | Omnipod |
| Exact Sciences Corporation | $36.89 | 2023-2024 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $34.65 | 2019-2024 | Gardasil, Vaxelis, Vaqta |
| Sanofi-Aventis U.S. LLC | $31.13 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $16.26 | 2025 | Uzedy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.28 | 2019 | |
| Ironshore Pharmaceuticals INC. | $14.00 | 2019 | |
| Sanofi Pasteur INC. | $13.71 | 2019 | |
| Lilly USA, LLC | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.